AbCellera on X

AbCellera (ABCL): The AI-Powered Drug Discovery Gem You've ...

x. Account Age, 17 years, scan comment · scan submission. TL;DR: - AbCellera Biologics Inc. (ABCL) is a game-changing player in the biotech ...

AbCellera and Lilly to Co-develop Antibody Therapies for the ...

AbCellera and Lilly will select from 500+ unique antibodies isolated from one of the first U.S. patients who recovered from COVID-19 to ...

AbCellera Reports Q1 2024 Business Results

AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2024. All financial information in this press release is ...

$ABCL - A Long Term Winning Gem Inside a Crowd of Some Dodgy ...

x x. Account Age, 2 months, scan comment · scan submission. Vote Spam (NEW), Click to Vote, Vote Approve (NEW), Click to Vote. Hey u/ ...

AbCellera to Report Second Quarter 2024 Financial Results on ...

AbCellera (Nasdaq: ABCL) will announce its second quarter 2024 financial results on Tuesday, August 6, 2024, and hold an earnings conference ...

Layoff Tracker: Sensei to Cut 46% of Workforce, Close Research Site

Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.

AbCellera Reports Q3 2024 Business Results

AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2024. All financial information in this press release is ...

AbCellera Announces Resignation of Board Member

AbCellera (Nasdaq: ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of ...

ASCPT News - 2024 - Clinical Pharmacology & Therapeutics

Learn more. Copy URL. Share a link. Share on. Email · Facebook · x ... AbCellera. Rosa Chan, PhD. Longboard Pharmaceuticals. Casey Davis, PhD.

Development of PSMA x CD3 T-cell engagers using an ... - AbCellera

Figure 2. T-cell profiling in cancer cell lines with high and low PSMA expression. bsAb 1 and 2 induce proliferation of CD4+ and CD8+ T-cell subsets, ...

Structure, function, surf, repeat: A week at Lorne Proteins 2024

X · Facebook · LinkedIn · Sina Weibo · Mendeley · Add ... X · Facebook · LinkedIn ... AbCellera, Labbot, or our long-standing sponsor, BMG LabTech.

Koyfin: Comprehensive financial data analysis

Koyfin provides tools for investors to research stocks & other asset classes. Koyfin covers equities, ETFs, mutual funds, forex, bonds, etc.

AbCellera Presents Data on Applications of T-Cell Engager Platform ...

AbCellera (Nasdaq: ABCL) today announced new data on its T-cell engager (TCE) platform, to be presented as a poster at the Society for ...

AbCellera Announces Multi-Target Research Collaboration with Pfizer

Vancouver, Canada (January 5, 2017) - AbCellera Biologics, Inc. announced today a new therapeutic antibody discovery collaboration with ...

Market Correction Incoming? My $100K Portfolio Reaches New Highs!

... Abcellera, Snowflake, and the ones mentioned before. Get Top 10 ... X: https://www.x.com/couch_investor $30 OFF Seeking Alpha ...

No. 17 Iowa State takes on Kansas at Arrowhead Stadium trying to ...

E96 D6C:6D[ 3FE x@H2 $E2E6 925 H@? E96 D6G6? AC:@C] ]]] %96 82>6 :D E2 ... AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 ...

Events & Presentations - AbCellera Biologics Inc. - Investor Relations

Evercore ISI AI x Therapeutics Day. Virtual. Webcast(opens in new window). May 18, 2021 11:00 AM PT. Berenberg Conference USA 2021. May 13, 2021 02:00 PM PT. Q1 ...

AbCellera Reports Q2 2024 Business Results

AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2024. All financial information in this press release ...

Eli Lilly and Company (LLY) Stock Price, Quote, News & Analysis

The chart has 2 X axes displaying Time, and Time. ... AbCellera Biologics Inc.; and Chugai ... The chart has 1 X axis displaying time periods. The chart ...

AbCellera, Viking Global Investors, and ArrowMark Partners ...

AbCellera (Nasdaq: ABCL), Viking Global Investors (“Viking”), and ArrowMark Partners (“ArrowMark”) announced today that they have entered ...